Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?

(2571) Views  (525) Full article downloads

Author: Roger M Pinder

Published Date February 2005 Volume 2005:1(1) Pages 3 - 7

DOI: http://dx.doi.org/10.2147/NDT.S

Roger M Pinder

Medical Affairs, CNS & Thrombosis, Organon International Inc, Oss, The Netherlands

Correspondence: Roger M Pinder, Vughterstraat 123D, 5211GA ´s-Hertogenbosch, The Netherlands Tel +31 73 610 4715 Email pinde003@planet.nl

Abstract: Noradrenaline has long played a key role in the way the etiology of depression is conceptualized and in the mechanism of action of many current antidepressants. Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), selective noradrenaline reuptake inhibitors (NRIs), the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine, and many atypicals, like mianserin and bupropion, influence, at least in part, central noradrenergic function. Enhancement of noradrenergic function may be particularly helpful in patients with melancholia. However, while noradrenaline will continue to be a target for research into the etiology and treatment of depression, it is unlikely that antidepressants acting solely on noradrenaline will be pursued.

Keywords: alpha2-adrenoceptors, antidepressants, depression, noradrenaline, reuptake